Bimatoprost sustained-release implant significantly reduces IOP with high patient satisfaction

A biodegradable bimatoprost-eluting implant compared favorably with topical bimatoprost in reducing IOP, according to a scientific poster presented at the European Glaucoma Society Congress in Prague. Keith R. Martin, MA, DM, MRCP, FRCOphth, reviewed 12-month results of a phase 1/2 clinical trial of the bimatoprost sustained-release implant (Bimatoprost SR, Allergan).